CFC 222

10/01/1998 - "These results indicate that CFC-222 is potentially useful for treating infection caused by penicillin-resistant strains of S. "
10/01/1997 - "In this infection model, CFC-222 was slightly less active than ciprofloxacin against Pseudomonas aeruginosa. "
10/01/1997 - "CFC-222 exhibited efficacy comparable to that of ciprofloxacin in the same model of infection caused by gram-negative organisms, such as E. "
10/01/1997 - "The in vivo protective efficacy of CFC-222 by oral administration was greater than those of the other quinolones tested in a mouse model of intraperitoneally inoculated systemic infection caused by S. "
02/01/1998 - "Against Escherichia coli, Klebsiella pneumoniae and Enterobacter cloacae infections, the efficacy of CFC-222 was similar to those of ciprofloxacin, ofloxacin and sparfloxacin. "

02/01/1998 - "These results suggest that CFC-222 may be a promising therapeutic agent for the treatment of various bacterial infections."
10/01/1997 - "These results suggest that CFC-222 may be a promising therapeutic agent in various bacterial infections."